Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. reported strong revenue growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $27.6 million from $17.6 million a year earlier, driven by expanding adoption of the iLet insulin delivery system and recurring single-use products across both durable medical equipment and pharmacy benefit channels.
Gross profit nearly doubled to $16.4 million, but rising investments in research and development, sales and marketing, and general and administrative functions pushed operating expenses to $40.7 million, resulting in a net loss of $21.9 million, an improvement from $28.7 million in the prior-year period. The company ended the quarter with $30.3 million in cash, cash equivalents and restricted cash and $209.2 million in short- and long-term investments, supporting ongoing commercialization and pipeline development, including a patch pump and a bihormonal iLet system.
Beta Bionics, Inc. reported strong first quarter 2026 growth and raised its full year 2026 outlook. Net sales reached $27.6 million, up 57% from $17.6 million a year earlier, driven by both Durable Medical Equipment and Pharmacy Benefit Plan channels.
Gross margin improved to 59.5% from 50.9%, while net loss narrowed to $21.9 million from $28.7 million as operating expenses increased to support growth. The company ended March 31, 2026 with $239.5 million in cash, cash equivalents, and investments and now expects 2026 revenue of $131–$136 million, higher gross margins, and a greater share of new patient starts through the PBP channel.
Beta Bionics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on May 21, 2026 at 2:00 P.M. Pacific Time, accessible via live audio webcast at www.virtualshareholdermeeting.com/BBNX2026 for holders as of March 23, 2026.
Stockholders are asked to elect two Class I directors, Sean Carney and Christy Jones, to terms ending at the 2029 annual meeting and to ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy also details board structure, committee responsibilities, executive compensation, equity plans, auditor fees and corporate governance policies, including risk oversight, cybersecurity and stockholder engagement.
Beta Bionics Inc ownership disclosure: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0% of the class as of 03/13/2026.
The filing is an amendment (Schedule 13G/A) reflecting an internal realignment at The Vanguard Group and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/26/2026.
Beta Bionics Chief Commercial Officer Mark Hopman sold 2,917 shares of Common Stock in open-market transactions, primarily to cover tax withholding tied to vested restricted stock units. The sales occurred at weighted average prices around $30–31 per share under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Hopman directly holds 136,216 shares of Beta Bionics Common Stock, indicating he retains a substantial equity stake in the company.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 1,025 shares of Common Stock at an average price of $29.3359 per share on December 2, 2025. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 178,071 shares directly.
Beta Bionics, Inc. reported that Chief Product Officer Mike Mensinger received a grant of employee stock options covering 91,520 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036. According to the disclosure, these options vest in 36 equal monthly installments starting on March 1, 2026, meaning the award vests gradually over three years as continued service is provided.
Beta Bionics, Inc. reported that its Chief Medical Officer, Russell Steven Jon, received a grant of stock options. The award covers 91,520 options to purchase common stock at an exercise price of $12.63 per share, expiring on February 26, 2036.
The options were granted at no cost and represent a compensation-related award rather than an open-market purchase. According to the vesting terms, the options will vest in 36 equal monthly installments starting on March 1, 2026, meaning the officer earns the right to exercise them gradually over three years.
Beta Bionics, Inc. reported that President & CEO Sean Saint received a grant of employee stock options on Common Stock. The award covers 287,944 options with an exercise price of $12.63 per share and an expiration date of February 26, 2036.
The options were granted at no cost and are classified as a compensation-related acquisition rather than an open-market purchase. According to the vesting terms, the underlying shares will vest in 36 equal monthly installments starting on March 1, 2026, aligning the CEO’s incentives with longer-term company performance.